Rx (Prescription Medicine)
USD $ 2,300.00
Crizalk 200mg Capsule 是一种靶向治疗药物，用于治疗某些类型的非小细胞肺癌（NSCLC）以及 ALK-阳性转移性乳腺癌。活性成分为 Crizotinib，通过抑制参与癌细胞生长和转移的特定酶（ALK 和 ROS1），从而发挥作用。通过阻断这些酶，Crizalk 有助于减缓或停止癌症的生长。通常用于肿瘤携带特定基因突变（ALK-阳性或 ROS1-阳性）的患者。常规剂量为 200mg，每日两次口服，可与食物同服或空腹服用。但具体剂量可能会根据个体的反应和耐受性由医疗专业人员进行调整。常见的不良反应可能包括视觉异常、恶心、呕吐、腹泻、便秘、疲劳、水肿以及肝酶升高。在服用前请告知医生您是否有既往疾病，尤其是肝脏或肺部问题，以及您正在使用的其他药物。Crizalk 200mg Capsule 应储存在室温下，避免潮湿和热源，并放置于儿童不易触及的地方。
| Medicine Form | |
|---|---|
| Rx Status | |
| Medicine Type | |
| Molecule | |
| Pack Quantity | |
| Brand Name | |
| Strength |
未库存此 exact 强度的其他品牌，因此这些是其他强度的 Crizotinib. 未经开方医生建议，请勿更改剂量。
医学审核
Renu Meena, B.Pharm
Medical Content Writer
Renu Meena is an experienced Medical Content Writer with a strong foundation in pharmacy practice. She holds a Bachelor of Pharmacy (B.Pharm) degree from Rajasthan University of Health Sciences (RUHS), Jaipur, and is registered with the Rajasthan State Pharmacy Council (Reg. No. 55661). With 4+ years of experience across clinical pharmacy and medical content development, she creates evidence-based content for medicines, diseases, and patient education. Her work is shaped by a strong understanding of pharmacovigilance and regulatory standards, including ICH guidelines, GVP modules, ICD-10/11, and safety reporting requirements. Renu focuses on making complex medical information simple, accurate, and useful for readers while maintaining high quality and compliance.
